A survey of subjects with present or previous atrial fibrillation in a Swedish community

Scandinavian Journal of Primary Health Care

Volumn 19, Issue 1, 2001, Pages 20-24

  Wandell P E ^a,b  

^a Husläkarna i Österåker Health Centre   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticoagulants; Atrial fibrillation; Cerebrovascular disorders; Sweden

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANTICOAGULATION; ARTICLE; BRAIN ISCHEMIA; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RISK FACTOR; SEX; STANDARDIZATION; SWEDEN; VALVULAR HEART DISEASE;

EID: 0035105381     PISSN: 02813432     EISSN: None     Source Type: Journal    
DOI: 10.1080/02813430118883     Document Type: Article

References (21)

1. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and applications
2. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates
3. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
4. Treatment of atrial fibrillation. Recommendations from a workshop arranged by the medical products agency (Uppsala, Sweden) and the Swedish society of cardiology
5. A survey of atrial fibrillation in general practice: The West Birmingham atrial fibrillation project
6. Atrial fibrillation and stroke prevention in the community
7. Risk factors for stroke efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
8. Prevention of thromboembolic events in atrial fibrillation
9. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke
10. Antithrombotic treatment to prevent stroke in patients with atrial fibrillation: A meta-analysis
11. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
12. From clinical trials to clinical practice: Oral anticoagulation among patients with non-rheumatic, atrial fibrillation
13. Why do patients with atrial fibrillation not receive warfarin?
14. Drug use in patients with atrial fibrillation in Swedish primary health care: A comparison 5 years apart
15. Five-year mortality in men and women with atrial fibrillation
16. Impact of atrial fibrillation on the risk of death: The Framingham heart Study
17. Paroxysmal atrial fibrillation: High frequency of embolic brain infarction in elderly autopsy patients
18. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation
19. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?
20. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: Effect of cardioversion to sinus rhythm
21. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients